Epithelial Tumors of the Ovary

  • Jeffrey D. SeidmanEmail author
  • Brigitte M. Ronnett
  • Ie-Ming Shih
  • Kathleen R. Cho
  • Robert J. Kurman
Living reference work entry

Latest version View entry history


Worldwide, ovarian cancer is the seventh most common cancer in women and the eighth most common cause of cancer death. There are about 239,000 new cases and 152,000 deaths annually (American Cancer Society 2015). In the Western hemisphere, ovarian cancer accounts for 4% of cancer in women and is the most frequent cause of death due to gynecological cancer. In American women, ovarian cancer represents 3% of all new cancers (SEER 2017). It ranks 11th in incidence and 5th in mortality and accounts for 5% of cancer deaths. It is estimated that in the USA in 2017, there are 22,440 new ovarian cancer cases and 14,080 deaths, making it the most lethal gynecologic malignancy (Siegel et al. 2017). Approximately 1.3% of American women will develop ovarian cancer in their lifetime, or 12 new cases per 100,000. In general, the disease is more common in industrialized countries where parity is lower, but there are notable exceptions such as Japan which has a low parity and low rate of ovarian cancer. The lifetime risk varies widely from 0.45% in Japan to 1.7% in Sweden. Annual incidence rates of ovarian cancer are lower in developing countries as compared to developed countries, averaging 5.0 and 9.1 per 100,000, respectively. Similarly, mortality rates average 3.1 and 5.0 per 100,000, respectively (American Cancer Society 2015). Denmark and other Scandinavian countries have among the highest annual incidence rates at greater than 16 per 100,000 women. Interestingly, as compared to all other common cancers, ovarian cancer varies the least in age-standardized incidence rates across registry populations worldwide (Bray et al. 2015). In the USA, incidence and mortality rates have been declining by 1.9% and 2.2% per year, respectively, from 2004 to 2013 (SEER 2017). Over longer periods, the incidence has been relatively stable worldwide from the 1970s to the 2000s. There have been, however, small but significant increases in Eastern and Southern Europe and Asia and decreases in Northern Europe and North America (Coburn et al. 2017). In addition, the incidence of ovarian carcinoma appears to have decreased as peritoneal and tubal carcinomas have increased, reflecting a recent change in classification. Migration studies have shown that ovarian cancer rates approach those of the place of immigration rather than the place of emigration, suggesting a significant environmental component to ovarian cancer risk.


  1. Agoff SN, Mendelin JE, Grieco VS et al (2002) Unexpected gynecologic neoplasms in patients with proven or suspected BRCA-1 or -2 mutations: implications for gross examination, cytology and clinical follow-up. Am J Surg Pathol 26:171–178PubMedCrossRefGoogle Scholar
  2. Ali RH, Seidman JD, Luk M, Kalloger S, Gilks CB (2012) Transitional cell carcinoma of the ovary is related to high-grade serous carcinoma and is distinct from malignant Brenner tumor. Int J Gynecol Pathol 31:499–506PubMedCrossRefGoogle Scholar
  3. Ali RH, Kalloger SE, Santos JL, Swenerton KD, Gilks CB (2013) Stage II to IV low-grade serous carcinoma of the ovary is associated with a poor prognosis: a clinicopathologic study of 32 patients from a population-based tumor registry. Int J Gynecol Pathol 32:529–535PubMedCrossRefGoogle Scholar
  4. Allemani C, Weir HK, Carreira H et al (2015) Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 385:977–1010PubMedCrossRefGoogle Scholar
  5. Allen VA, Takashima Y, Nayak S, Manahan KJ, Geisler JP (2017) Assessment of false-negative ascites cytology in epithelial ovarian carcinoma: a study of 313 patients. Am J Clin Oncol 40:175–177PubMedCrossRefGoogle Scholar
  6. American Cancer Society (2015) Global cancer: facts and figures, 3rd edn. American Cancer Society, AtlantaGoogle Scholar
  7. Anglesio MS, Carey MS, Kobel M et al (2011) Clear cell carcinoma of the ovary: a report from the first ovarian clear cell symposium, June 24th 2010. Gynecol Oncol 121:407–415PubMedCrossRefGoogle Scholar
  8. Anglesio MS, Bashashati A, Wang YK et al (2015) Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden. J Pathol 236:201–209PubMedCrossRefGoogle Scholar
  9. Anglesio MS, Wang YK, Maassen M et al (2016) Synchronous endometrial and ovarian carcinomas: evidence of clonality. J Natl Cancer Inst 108:djv428PubMedCrossRefGoogle Scholar
  10. Anglesio MS, O’Neill CJ, Senz J, Gilks CB, McCluggage WG (2017) Identical TP53 mutations provide evidence that late recurring tubo-ovarian high grade serous carcinomas do not represent new peritoneal primaries. Histopathology 71:1014–1017PubMedCrossRefGoogle Scholar
  11. Ardighieri L, Lonardi S, Moratto D, Faccetti F, Shih I-M, Vermi W, Kurman RJ (2014a) Characterization of the immune cell repertoire in the normal fallopian tube. Int J Gynecol Pathol 33:581–591PubMedPubMedCentralCrossRefGoogle Scholar
  12. Ardighieri L, Zeppernick F, Hannibal CG et al (2014b) Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants. J Pathol 232:16–22PubMedPubMedCentralCrossRefGoogle Scholar
  13. Ardighieri L, Mori L, Conzadori S et al (2016) Identical TP53 mutations in pelvic carcinosarcomas and associated serous tubal intraepithelial carcinomas provide evidence of their clonal relationship. Virchows Arch 469:61–69PubMedCrossRefGoogle Scholar
  14. Ataseven B, Chiva LM, Harter P, Gonzalez-Martin A, du Bois A (2016a) FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited. Gynecol Oncol 142:597–607PubMedCrossRefGoogle Scholar
  15. Ataseven B, duBois A, Harter P et al (2016b) Impact of abdominal wall metastases on prognosis in epithelial ovarian cancer. Int J Gynecol Cancer 26:1594–1600PubMedCrossRefGoogle Scholar
  16. Auersperg N (2013) Ovarian surface epithelium as a source of ovarian cancers: unwarranted speculation or evidence-based hypothesis? Gynecol Oncol 130:246–251PubMedCrossRefGoogle Scholar
  17. Auersperg N, Woo MMM, Gilks CB (2008) The origin of ovarian carcinomas: a developmental view. Gynecol Oncol 110:452–454PubMedCrossRefPubMedCentralGoogle Scholar
  18. Aune D, Rosenblatt DAN, Chan DSM et al (2015) Anthropometric factors and ovarian cancer risk: a systematic review and nonlinear dose-response meta-analysis of prospective studies. Int J Cancer 136:1888–1898PubMedCrossRefPubMedCentralGoogle Scholar
  19. Ayhan A, Kurman RJ, Yemelyanova A, Vang R, Logani S, Seidman JD, Shih IM (2009) Defining the cut point between low-grade and high-grade ovarian serous carcinoma: a clinicopathologic and molecular genetic analysis. Am J Surg Pathol 33:1220–1224PubMedPubMedCentralCrossRefGoogle Scholar
  20. Ayres C, Ratnayake G, McNally O, Quinn M (2017) Challenging salpingectomy as a risk-reducing measure for ovarian cancer: histopathological analysis of the tubo-ovarian interface in women undergoing risk-reducing salpingo-oophorectomy. Int J Gynecol Cancer 27:703–707PubMedCrossRefGoogle Scholar
  21. Azami S, Aoki Y, Iino M et al (2018) Useful aspects of diagnosis of imprint cytology in intraoperative consultation of ovarian tumors: comparison between imprint cytology and frozen sections. Diagn Cytopathol 46:28–34PubMedCrossRefGoogle Scholar
  22. Bachmayr-Heyda A, Aust S, Heinze G et al (2013) Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients- a study of the OVCAD consortium. BMC Cancer 13:422PubMedPubMedCentralCrossRefGoogle Scholar
  23. Bahar-Shany K, Brand H, Sapoznik S et al (2014) Exposure of fallopian tube epithelium to follicular fluid mimics carcinogenic changes in precursor lesions of serous papillary carcinoma. Gynecol Oncol 132:322–327PubMedCrossRefGoogle Scholar
  24. Bakkum-Gamez J, Dowdy S (2014) Retooling the pap smear for ovarian and endometrial cancer detection. Clin Chem 60:22–24PubMedCrossRefGoogle Scholar
  25. Baldwin LA, Chen Q, Tucker TC, White CG, Ore RN, Huang B (2017) Ovarian cancer incidence corrected for oophorectomy. Diagnostics 7:19PubMedCentralCrossRefPubMedGoogle Scholar
  26. Bamias A, Psaltopoulou T, Sotiropoulou M et al (2010) Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy. Cancer 116:1462–1468PubMedCrossRefGoogle Scholar
  27. Bamias A, Karadimou A, Soupos N et al (2011) Prognostic factors for early stage epithelial ovarian cancer, treated with adjuvant carboplatin/paclitaxel chemotherapy: a single institution experience. Gynecol Oncol 123:37–42PubMedCrossRefGoogle Scholar
  28. Bamias A, Sotiropoulou M, Zagouri F et al (2012) Prognostic evaluation of tumor types and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel/carboplatin chemotherapy: cell type is the most important prognostic factor. Eur J Cancer 48:1476–1483PubMedCrossRefGoogle Scholar
  29. Banet N, Kurman RJ (2015) Two types of ovarian cortical inclusion cysts: proposed origin and possible role in ovarian serous carcinogenesis. Int J Gynecol Pathol 34:3–8PubMedCrossRefGoogle Scholar
  30. Baque S, Rodriguez IM, Prat J (2002) Sarcoma-like mural nodules in mucinous cystic tumors of the ovary revisited: a clinicopathologic analysis of 10 additional cases. Am J Surg Pathol 26:1467–1476CrossRefGoogle Scholar
  31. Barber EL, Dusetzina SB, Stitzenberg KB et al (2017) Variation in neoadjuvant chemotherapy utilization for epithelial ovarian cancer at high volume hospitals in the United States and associated survival. Gynecol Oncol 145:500–507PubMedPubMedCentralCrossRefGoogle Scholar
  32. Bennett JA, Dong F, Young RH, Oliva E (2015) Clear cell carcinoma of the ovary: evaluation of prognostic parameters based on a clinicopathological analysis of 100 cases. Histopathology 66:808–815PubMedCrossRefGoogle Scholar
  33. Berek JS, Crum C, Friedlander M (2015) Cancer of the ovary, fallopian tube and peritoneum. Int J Gynecol Obstet 131:S111–S122CrossRefGoogle Scholar
  34. Berge W, Mundt K, Luu H, Boffetta P (2018) Genital use of talc and risk of ovarian cancer: a meta-analysis. Eur J Cancer Prev. 27:248–57
  35. Blanco LZ, Kuhn E, Morrison JC, Bahadirli-Talbott A, Smith-Sehdev A, Kurman RJ (2017) Steroid hormone synthesis by the ovarian stroma surrounding epithelial ovarian tumors: a potential mechanism in ovarian tumorigenesis. Mod Pathol 30:563–576PubMedCrossRefGoogle Scholar
  36. Bodelon C, Wentzensen N, Schonfeld SJ et al (2013) Hormonal risk factors and invasive epithelial ovarian cancer risk by parity. Br J Cancer 109:769–776PubMedPubMedCentralCrossRefGoogle Scholar
  37. Bodelon C, Pfeiffer RM, Buys SS, Black A, Sherman ME (2014) Analysis of serial ovarian volume measurements and incidence of ovarian cancer: implications for pathogenesis. J Natl Cancer Inst 106:dju262PubMedPubMedCentralCrossRefGoogle Scholar
  38. Bodurka DC, Deavers MT, Tian C et al (2012) Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group study. Cancer 118:3087–3094PubMedCrossRefGoogle Scholar
  39. Bohm S, Faruqi A, Said I et al (2015) Chemotherapy response score development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. J Clin Oncol 33:2457–2463PubMedCrossRefGoogle Scholar
  40. Bolton KL, Chenevix-Trench G, Goh C et al (2012) Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 307:382–390PubMedPubMedCentralCrossRefGoogle Scholar
  41. Bouchard-Fortier G, Panzarella T, Rosen B, Chapman W, Gien LT (2017) Endometrioid carcinoma of the ovary: outcomes compared to serous carcinoma after 10 years of follow-up. J Obstet Gynaecol Can 39:34–41PubMedCrossRefGoogle Scholar
  42. Boyd C, McCluggage WG (2012) Low-grade ovarian serous neoplasms (low-grade serous carcinoma and serous borderline tumor) associated with high-grade serous carcinoma or undifferentiated carcinoma: report of a series of cases of an unusual phenomenon. Am J Surg Pathol 36:368–375PubMedCrossRefGoogle Scholar
  43. Bray F, Ferlay J, Laversanne M et al (2015) Cancer incidence in five continents: inclusion criteria, highlights from volume X and the global status of cancer registration. Int J Cancer 137:2060–2071PubMedCrossRefGoogle Scholar
  44. Brinton LA, Gridley G, Persson I, Baron J, Bergqvist A (1997) Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol 176:572–579PubMedCrossRefGoogle Scholar
  45. Bristow RE, Chang J, Ziogas A, Randall LM, Anton-Culver H (2014) High-volume ovarian cancer care: survival impact and disparities in access for advanced-stage disease. Gynecol Oncol 132:403–410PubMedCrossRefGoogle Scholar
  46. Bromley AB, Altman AD, Chu P et al (2012) Architectural patterns of ovarian/pelvic high grade serous carcinoma. Int J Gynecol Pathol 31:397–404PubMedCrossRefGoogle Scholar
  47. Bruls J, Simons M, Overbeek LI, Bulten J, Massuger LF, Nagtegaal ID (2015) A national population-based study provides insight into the origin of malignancies metastatic to the ovary. Virchows Arch 467:79–86PubMedPubMedCentralCrossRefGoogle Scholar
  48. Burks RT, Sherman ME, Kurman RJ (1996) Micropapillary serous carcinoma of the ovary: a distinctive low-grade carcinoma related to serous borderline tumors. Am J Surg Pathol 20:1319–1330PubMedCrossRefGoogle Scholar
  49. Buttarelli M, Mascilini F, Zannoni GF et al (2017) Hormone receptor expression profile of low-grade serous ovarian cancers. Gynecol Oncol 145:352–360PubMedCrossRefGoogle Scholar
  50. Buys SS, Partridge E, Black A et al (2011) Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. JAMA 305:2295–2303PubMedCrossRefGoogle Scholar
  51. Cancer Research UK (2017) Original data source: the National Cancer Registration Service, Eastern Office. Accessed 27 Aug 2017.Google Scholar
  52. Carlson JW, Miron A, Jarboe EA et al (2008) Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol 26:4160–4165PubMedPubMedCentralCrossRefGoogle Scholar
  53. Carr NJ, Cecil TD, Mohamed F et al (2016) A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the Peritoneal surface oncology group international (PSOGI) modified delphi process. Am J Surg Pathol 40:14–26PubMedCrossRefGoogle Scholar
  54. Casey L, Kobel M, Ganesan R et al (2017) A comparison of p53 and WT1 immuno-histochemical expression patterns in tubo-ovarian high grade serous carcinoma before and after neoadjuvant chemotherapy. Histopathology 71:736–742PubMedCrossRefGoogle Scholar
  55. Cass I, Walts AE, Barbuto D, Lester J, Karlan B (2014) A cautious view of putative precursors of serous carcinomas in the fallopian tubes of BRCA mutation carriers. Gynecol Oncol 134:492–497PubMedCrossRefGoogle Scholar
  56. Chay WY, McCluggage WG, Lee CH et al (2016) Outcomes of incidental fallopian tube high-grade serous carcinoma and serous tubal intraepithelial carcinoma in women at low risk of hereditary breast and ovarian cancer. Int J Gynecol Pathol 26:431–436CrossRefGoogle Scholar
  57. Chen S, Leitao MM, Tornos C et al (2005) Invasion patterns in stage I endometrioid and mucinous ovarian carcinomas: a clinicopathologic analysis emphasizing favorable outcomes in carcinomas without destructive stromal invasion and the occasional malignant course of carcinomas with limited destructive stromal invasion. Mod Pathol 18:903–911PubMedCrossRefGoogle Scholar
  58. Chen F, Gaitskell K, Garcia MJ, Albukhari A, Tsaltas J, Ahmed AA (2017) Serous tubal intraepithelial carcinomas associated with high grade serous ovarian carcinomas: a systematic review. Br J Obstet Gynaecol 124:872–878CrossRefGoogle Scholar
  59. Chiesa AG, Deavers MT, Veras E, Silva EG, Gershenson D, Malpica A (2010) Ovarian intestinal type mucinous borderline tumors: are we ready for a nomenclature change? Int J Gynecol Pathol 29:108–112PubMedCrossRefGoogle Scholar
  60. Cho K, Shih I-M (2009) Ovarian cancer. Annu Rev Pathol Mech Dis 4:287–313CrossRefGoogle Scholar
  61. Chui MH, Gilks CB, Cooper K, Clarke BA (2013) Identifying Lynch syndrome in patients with ovarian carcinoma: the significance of tumor subtype. Adv Anat Pathol 20:378–386PubMedCrossRefGoogle Scholar
  62. Chui MH, Ryan P, Radigan J et al (2014) The histomorphology of Lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategy. Am J Surg Pathol 38:1173–1181PubMedCrossRefGoogle Scholar
  63. Chung HH, Hwang SY, Jung KW et al (2007) Ovarian cancer incidence and survival in Korea. Int J Gynecol Cancer 17:595–600PubMedCrossRefGoogle Scholar
  64. Cibula D, Widschwendter M, Majek O, Dusek L (2011a) Tubal ligation and the risk of ovarian cancer: review and meta-analysis. Hum Reprod Update 17:55–67PubMedCrossRefGoogle Scholar
  65. Cibula D, Zikan M, Dusek L, Majek O (2011b) Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Expert Rev Anticancer Ther 11:1197–1207PubMedCrossRefGoogle Scholar
  66. Coburn SB, Bray F, Sherman ME, Trabert B (2017) International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. Int J Cancer 140:2451–2460PubMedPubMedCentralCrossRefGoogle Scholar
  67. Coghlan E, Meniawy TM, Munro A et al (2017) Prognostic role of histological tumor regression in patients receiving neoadjuvant chemotherapy for high-grade serous tubo-ovarian carcinoma. Int J Gynecol Cancer 27:708–713PubMedCrossRefGoogle Scholar
  68. Collaborative Group on Epidemiological Studies of Ovarian Cancer (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371:303–314CrossRefGoogle Scholar
  69. Colon E, Carlson JW (2014) Evaluation of the fallopian tubes after neoadjuvant chemotherapy: persistence of serous tubal intraepithelial carcinoma. Int J Gynecol Pathol 33:463–469PubMedCrossRefGoogle Scholar
  70. Conner JR, Meserve E, Pizer E et al (2014) Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations. Gynecol Oncol 132:280–286PubMedCrossRefGoogle Scholar
  71. Cormio G, Loizzi V, Falagario M et al (2011) Central nervous system metastases from epithelial ovarian cancer: prognostic factors and outcomes. Int J Gynecol Cancer 21:816–821PubMedCrossRefGoogle Scholar
  72. Crane TE, Khulpateea BR, Alberts DS, Basen-Engquist K, Thomson CA (2014) Dietary intake and ovarian cancer risk: a systematic review. Cancer Epidemiol Biomark Prev 23:255–273CrossRefGoogle Scholar
  73. Crane EK, Sun CC, Ramirez PT, Schmeler KM, Malpica A, Gershenson DM (2015) The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer. Gynecol Oncol 136:25–29PubMedCrossRefGoogle Scholar
  74. Crum CP, Herfs M, Ning G et al (2013) Through the glass darkly: intraepithelial neoplasia, top-down differentiation, and the road to ovarian cancer. J Pathol 231:402–412PubMedPubMedCentralCrossRefGoogle Scholar
  75. Dahm-Kahler P, Borgfeldt C, Holmberg E et al (2017) Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin- on behalf of the Swedish gynecological cancer group (SweGCG). Gynecol Oncol 144:167–173PubMedCrossRefGoogle Scholar
  76. Damiani D, Suciu V, Genestie C, Vielh P (2016) Cytomorphology of ovarian clear cell carcinomas in peritoneal effusions. Cytopathology 27:427–432PubMedCrossRefGoogle Scholar
  77. Dao F, Schlappe BA, Tseng J et al (2016) Characteristics of 10-year survivors of high-grade serous ovarian carcinoma. Gynecol Oncol 141:260–263PubMedPubMedCentralCrossRefGoogle Scholar
  78. Dehari R, Kurman RJ, Logani S, Shih I-M (2007) The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma. A morphologic and molecular genetic analysis. Am J Surg Pathol 31:1007–1012PubMedCrossRefGoogle Scholar
  79. DeLair D, Han G, Irving JA et al (2013) HNF-1β in ovarian carcinomas with serous and clear cell change. Int J Gynecol Pathol 32:541–546PubMedPubMedCentralCrossRefGoogle Scholar
  80. Dent J, Hall GD, Wilkinson N et al (2003) Cytogenetic alterations in ovarian clear cell carcinoma detected by comparative genomic hybridization. Br J Cancer 88:1578–1583PubMedPubMedCentralCrossRefGoogle Scholar
  81. Dixon SC, Nagle CM, Thrift AP et al (2016) Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. Int J Epidemiol 45:884–895PubMedPubMedCentralCrossRefGoogle Scholar
  82. Dizon DS, Birrer MJ (2016) Making a difference: distinguishing two primaries from metastasis in synchronous tumors of the ovary and uterus. J Natl Cancer Inst 108:djv442PubMedCrossRefGoogle Scholar
  83. Dobrinski K, Esposito NN, Kruk PA et al (2014) Procurement and cytological features of human fallopian tube fimbrial cells by ex vivo imprinting and washing. J Am Soc Cytopathol 3:309–318CrossRefGoogle Scholar
  84. Doo DW, Erickson B, Arend RC, Conner MG, Huh WK, Leath CA (2014) Radical surgical cytoreduction in the treatment of ovarian carcinosarcoma. Gynecol Oncol 133:234–237PubMedCrossRefGoogle Scholar
  85. Du Bois A, Ewald-Riegler N, de Gregorio N et al (2013) Borderline tumors of the ovary: a cohort study of the Arbeitsgmeinschaft Gynakologische Onkologie (AGO) study group. Eur J Cancer 49:1905–1914PubMedCrossRefGoogle Scholar
  86. Dubeau L (1999) The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes? Gynecol Oncol 72:437–442PubMedCrossRefGoogle Scholar
  87. Ducie J, Dao F, Considine M, Olvera N, Shaw PA, Kurman RJ, Shih IM, Soslow RA, Cope L, Levine DA (2017) Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma. Nat Commun 8:990PubMedPubMedCentralCrossRefGoogle Scholar
  88. Ebell MH, Culp MB, Radke TJ (2016) A systematic review of symptoms for the diagnosis of ovarian cancer. Am J Prev Med 50:384–394PubMedCrossRefGoogle Scholar
  89. Eckert MA, Pan S, Hernandez KM et al (2016) Genomics of ovarian cancer progression reveals diverse metastatic trajectories including intraepithelial metastasis to the fallopian tube. Cancer Discov 6:1342–1351PubMedPubMedCentralCrossRefGoogle Scholar
  90. Eichorn JH, Young RH, Clement PB et al (2002) Mesodermal (Mullerian) adenosarcoma of the ovary: a clinicopathologic analysis of 40 cases and review of the literature. Am J Surg Pathol 26:1243–1258CrossRefGoogle Scholar
  91. Elishaev E, Gilks CB, Miller D et al (2005) Synchronous and metachronous endocervical and ovarian neoplasms: evidence supporting interpretation of the ovarian neoplasms as metastatic endocervical adenocarcinomas simulating primary ovarian surface epithelial neoplasms. Am J Surg Pathol 29:281–291PubMedCrossRefGoogle Scholar
  92. Erickson BK, Kinde I, Dobbin ZC et al (2014) Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer. Obstet Gynecol 124:881–885PubMedPubMedCentralCrossRefGoogle Scholar
  93. Escobar J, Klimowicz AC, Dean M et al (2013) Quantification of ER/PR expression in ovarian low-grade serous carcinoma. Gynecol Oncol 128:371–376PubMedCrossRefGoogle Scholar
  94. Esselen KM, Ng SK, Hua Y et al (2014) Endosalpingiosis as it relates to tubal, ovarian and serous neoplastic tissues: an immunohistochemical study of tubal and Mullerian antigens. Gynecol Oncol 132:316–321PubMedCrossRefGoogle Scholar
  95. Fader AN, Java J, Ueda S et al (2013) Survival in women with grade 1 serous ovarian carcinoma. Obstet Gynecol 122:225–232PubMedPubMedCentralCrossRefGoogle Scholar
  96. Fader AN, Bergstrom J, Jernigan A et al (2017) Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: reducing overtreatment without compromising survival? Gynecol Oncol 147:85–91PubMedCrossRefGoogle Scholar
  97. Falconer H, Yin L, Grönberg H, Altman DJ (2015) Ovarian cancer risk after salpingectomy: a nationwide population-based study. J Natl Cancer Inst 107:dju410PubMedCrossRefGoogle Scholar
  98. Flesken-Nikitin A, Hwang CI, Cheng CY, Michurina TV, Enikolopov G, Nikitin AY (2013) Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche. Nature 495:241–245PubMedPubMedCentralCrossRefGoogle Scholar
  99. Fotopolou C, Hall M, Cruickshank D et al (2017a) British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice. Eur J Obstet Gynaecol Repr Biol 213:123–139CrossRefGoogle Scholar
  100. Fotopolou C, Sehouli J, Aletti G et al (2017b) Value of neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer: a European perspective. J Clin Oncol 35:587–590CrossRefGoogle Scholar
  101. Fuh KC, Shin JY, Kapp DS et al (2015) Survival differences of Asian and Caucasian epithelial ovarian cancer patients in the United States. Gynecol Oncol 136:491–497PubMedCrossRefGoogle Scholar
  102. Fujiwara M, McGuire VA, Felberg A, Sieh W, Whittemore AS, Longacre TA (2012) Prediction of BRCA1 germline mutation status in women with ovarian cancer using morphology-based criteria: identification of a BRCA1 ovarian cancer phenotype. Am J Surg Pathol 36:1170–1177PubMedPubMedCentralCrossRefGoogle Scholar
  103. Gan C, Chenoy R, Chandrasekaran D et al (2017) Persistence of fimbrial tissue on the ovarian surface after salpingectomy. Am J Obstet Gynecol 217:425.e1–425.e16CrossRefGoogle Scholar
  104. Garg K, Zahurak ML, Trimble EL et al (2005) Abdominal carcinomatosis in women with a history of breast cancer. Gynecol Oncol 99:65–70PubMedCrossRefGoogle Scholar
  105. Garg K, Levine DA, Olvera N et al (2013) BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas. Am J Surg Pathol 37:138–146PubMedPubMedCentralCrossRefGoogle Scholar
  106. Gilks CB, Irving J, Kobel M et al (2015) Incidental nonuterine high-grade serous carcinomas arise in the fallopian tube in most cases: further evidence for the tubal origin of high-grade serous carcinomas. Am J Surg Pathol 39:357–364PubMedCrossRefGoogle Scholar
  107. Gilks CB, Movahedi-Lankarani S, Baker PM et al (2016) Protocol for the examination of specimens from patients with primary tumors of the ovary or fallopian tube. College of American Pathologists. Protocol web posting date: January 2016. Available at
  108. Gockley A, Melamed A, Bregar AJ et al (2017) Outcomes of women with high-grade and low-grade advanced-stage serous epithelial ovarian cancer. Obstet Gynecol 129:439–447PubMedPubMedCentralCrossRefGoogle Scholar
  109. Godoy H, Mhawech-Fauceglia P, Beck A, Miller A, Lele S, Odunsi K (2011) Expression of poly (adenosine diphosphate-ribose) polymerase and p53 in epithelial ovarian cancer and their role in prognosis and disease outcome. Int J Gynecol Pathol 30:139–144PubMedPubMedCentralCrossRefGoogle Scholar
  110. Gokcu M, Gungorduk K, Asicioglu O et al (2016) Borderline ovarian tumors: clinical characteristics, management and outcomes- a multicenter study. J Ovar Res 9:66CrossRefGoogle Scholar
  111. Goldberg A, Hand L, DeCotiis D, Rosenblum N, Chan J (2018) Microcystic, elongated, and fragmented pattern invasion in ovarian endometrioid carcinoma: immunohistochemical profile and prognostic implications. Int J Gynecol Pathol 37:44–51PubMedGoogle Scholar
  112. Guseh SH, Rauh-Hain A, Tambouret RH et al (2014) Transitional cell carcinoma of the ovary: a case-control study. Gynecol Oncol 132:649–653PubMedCrossRefGoogle Scholar
  113. Hakim SA, Youssef NS (2017) Diagnostic utility of thyroid transcription factor-1 in ovarian carcinoma and its relationship with clinicopathologic prognostic parameters. Appl Immunohistochem Mol Morphol 25:237–243PubMedCrossRefGoogle Scholar
  114. Hannibal CG, Vang R, Junge J, Kjaerbye-Thygesen A, Kurman RJ, Kjaer SK (2012) A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Denmark 1978–2006. Gynecol Oncol 125:655–660PubMedCrossRefGoogle Scholar
  115. Hannibal CG, Vang R, Junge J et al (2014) A nationwide study of serous “borderline” ovarian tumors in Denmark 1978–2002: centralized pathology review and overall survival compared with the general population. Gynecol Oncol 134:267–273PubMedPubMedCentralCrossRefGoogle Scholar
  116. Harmsen MG, Piek JMJ, Bulten J et al (2018) Peritoneal carcinomatosis after risk-reducing surgery in BRCA1/2 mutation carriers. Cancer. 124:952–8. Scholar
  117. Harter P, Reuss A, Sehouli J, Chiva L, duBois A (2017) Brief report about the role of hyperthermic intraperitoneal chemotherapy in a prospective randomized phase 3 study in recurrent ovarian cancer from Spiliotis et al. Int J Gynecol Cancer 27:246–247PubMedCrossRefGoogle Scholar
  118. Heintz APM, Odicino F, Maisonneuve P et al (2006) Carcinoma of the ovary. Int J Gynecol Obstet 95(Suppl 1):S161–S192CrossRefGoogle Scholar
  119. Henderson JT, Webber EM, Sawaya GF (2018) Screening for ovarian cancer: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 319:595–606PubMedCrossRefGoogle Scholar
  120. Higashi M, Kajiyama H, Shibata K, Mizuno M, Mizuno K, Hosono S (2011) Survival impact of capsule rupture in stage I clear cell carcinoma of the ovary in comparison with other histological types. Gynecol Oncol 123:474–478PubMedCrossRefGoogle Scholar
  121. Hjortkjaer M, Waldstrom M, Jakobsen A, Kanstrup H, Sogaard-Andersen E, Steffensen KD (2017) The prognostic value of BRCA1 and PARP expression in epithelial ovarian carcinoma: immunohistochemical detection. Int J Gynecol Pathol 36:180–189PubMedGoogle Scholar
  122. Hoang LN, Zachara S, Soma A et al (2015) Diagnosis of ovarian carcinoma histotype based on limited sampling: a prospective study comparing cytology, frozen section, and core biopsies to full pathologic examination. Int J Gynecol Pathol 34:517–527PubMedCrossRefGoogle Scholar
  123. Hoerl HD, Hart WR (1998) Primary ovarian mucinous cystadenocarcinomas: a clinicopathologic study of 49 cases with long-term follow-up. Am J Surg Pathol 22:1449–1462PubMedCrossRefGoogle Scholar
  124. Horn LC, Kafkova S, Leonhardt K, Kellner C, Einenkel J (2013) Serous tubal in situ carcinoma (STIC) in primary peritoneal serous carcinomas. Int J Gynecol Pathol 32:339–344PubMedCrossRefGoogle Scholar
  125. Horn LC, Hohn AK, Einenkel J, Siebolts U (2014) Monoclonal origin of peritoneal implants and lymph node deposits in serous borderline ovarian tumors (s-BOT) with high intratumoral heterogeneity. Int J Gynecol Pathol 33:592–597PubMedCrossRefPubMedCentralGoogle Scholar
  126. Hoskins PJ, Le N, Gilks B et al (2012) Low-stage ovarian clear cell carcinoma: population-based outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradiation. J Clin Oncol 30:1656–1662PubMedCrossRefPubMedCentralGoogle Scholar
  127. Howitt BE, Hanamornroongruang S, Lin DI et al (2015) Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma. Am J Surg Pathol 39:287–293PubMedCrossRefPubMedCentralGoogle Scholar
  128. Hu A, Li H, Zhang L et al (2015) Differentiating primary and extragenital metastatic mucinous ovarian tumours: an algorithm combining PAX8 with tumour size and laterality. J Clin Pathol 68:522–528PubMedPubMedCentralCrossRefGoogle Scholar
  129. Hunter SM, Anglesio MS, Sharma R et al (2011) Copy number aberrations in benign serous ovarian tumors: a case for reclassification? Clin Cancer Res 17:7273–7282PubMedCrossRefGoogle Scholar
  130. Hussein YR, Ducie JA, Arnold AG et al (2016) Invasion patterns of metastatic extrauterine high-grade serous carcinoma with BRCA germline mutation and correlation with clinical outcomes. Am J Surg Pathol 40:404–409PubMedPubMedCentralCrossRefGoogle Scholar
  131. Irving JA, Clement PB (2011) Diseases of the peritoneum. In: Kurman RJ et al (eds) Blaustein’s pathology of the female genital tract, 6th edn. Springer, New York, pp 625–678CrossRefGoogle Scholar
  132. Irving JA, Clement PB (2014) Recurrent intestinal mucinous borderline tumors of the ovary: a report of 5 cases causing problems in diagnosis, including distinction from mucinous carcinoma. Int J Gynecol Pathol 33:156–165PubMedCrossRefGoogle Scholar
  133. Jacobs IJ, Menon U, Ryan A et al (2016) Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet Oncol 387:945–956CrossRefGoogle Scholar
  134. Jain V, Sekhon R, Pasricha S et al (2017) Clinicopathological characteristics and prognostic factors of synchronous endometrial and ovarian cancers- a single institute review of 43 cases. Int J Gynecol Cancer 27:938–946PubMedCrossRefGoogle Scholar
  135. Jensen KC, Mariappan MR, Pitcha GV et al (2008) Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger. Am J Surg Pathol 32:1029–1037PubMedCrossRefGoogle Scholar
  136. Jia L, Yuan Z, Wang Y et al (2015) Primary sources of pelvic serous cancer in patients with endometrial intraepithelial carcinoma. Mod Pathol 28:118–127PubMedCrossRefPubMedCentralGoogle Scholar
  137. Jones S, Wang TL, Shih IM et al (2010) Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330:228–231PubMedPubMedCentralCrossRefGoogle Scholar
  138. Jones S, Wang TL, Kurman RJ et al (2012) Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol 226:413–420PubMedCrossRefGoogle Scholar
  139. Jordan SJ, Green AC, Whiteman DC et al (2007) Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiologic evidence of a neoplastic continuum? Gynecol Oncol 107:223–230PubMedCrossRefGoogle Scholar
  140. Jordan SJ, Nagle CM, Coory MD (2013) Has the association between hysterectomy and ovarian cancer changed over time? A systematic review and meta-analysis. Eur J Cancer 49:3638–3647PubMedCrossRefPubMedCentralGoogle Scholar
  141. Judson K, McCormick C, Vang R et al (2008) Women with undiagnosed colorectal adenocarcinomas presenting with ovarian metastases: clinicopathologic features and comparison with women having known colorectal adenocarcinomas and ovarian involvement. Int J Gynecol Pathol 27:182–190PubMedPubMedCentralGoogle Scholar
  142. Kalapotharakos G, Hogberg T, Bergfeldt K, Borgfeldt C (2016) Long-term survival in women with borderline ovarian tumors: a population-based survey of borderline ovarian tumors in Sweden 1960–2007. Acta Obstet Gynecol Scand 95:473–479PubMedCrossRefPubMedCentralGoogle Scholar
  143. Kanska J, Zakhour M, Taylor-Harding B, Karlan BY, Wiedemeyer WR (2016) Cyclin E as a potential therapeutic target in high grade serous ovarian cancer. Gynecol Oncol 143:152–158PubMedCrossRefPubMedCentralGoogle Scholar
  144. Kao YC, Lin MC, Lin WC et al (2012) Utility of hepatocyte nuclear factor-1β as a diagnostic marker in ovarian carcinomas with clear cells. Histopathology 61:760–768PubMedCrossRefGoogle Scholar
  145. Karam AK, Stempel M, Barakat R et al (2009) Patients with a history of epithelial ovarian cancer presenting with a breast and/or axillary mass. Gynecol Oncol 112:490–495PubMedCrossRefPubMedCentralGoogle Scholar
  146. Karamurzin Y, Leitao MM, Soslow RA (2013) Clinicopathologic analysis of low-stage sporadic ovarian carcinomas: a reappraisal. Am J Surg Pathol 37:356–367PubMedCrossRefGoogle Scholar
  147. Karnezis AN, Aysal A, Zaloudek CJ, Rabban JT (2013) Transitional cell-like morphology in ovarian endometrioid carcinoma: morphologic, immunohistochemical, and behavioral features distinguishing it from high-grade serous carcinoma. Am J Surg Pathol 37:24–37PubMedCrossRefGoogle Scholar
  148. Ketabi Z, Bartuma K, Bernstein I et al (2011) Ovarian cancer linked to lynch syndrome typically presents as early-onset, non-serous epithelial tumors. Gynecol Oncol 121:462–465PubMedCrossRefPubMedCentralGoogle Scholar
  149. Khedmati F, Chirolas C, Seidman JD (2009) Ovarian and para-ovarian squamous-lined cysts (epidermoid cysts): a clinicopathologic study of 18 cases with comparison to mature cystic teratomas. Int J Gynecol Pathol 28:193–196PubMedCrossRefPubMedCentralGoogle Scholar
  150. Khunamornpong S, Settakorn J, Sukpan K et al (2011) Mucinous tumor of low malignant potential (“borderline” or “atypical proliferative” tumor) of the ovary: a study of 171 cases with the assessment of intraepithelial carcinoma and microinvasion. Int J Gynecol Pathol 30:218–230PubMedCrossRefGoogle Scholar
  151. Khunamornpong S, Settakorn J, Sukpan K, Suprasert P, Siriaunkgul S (2014) Primary ovarian mucinous adenocarcinoma of intestinal type: a clinicopathologic study of 46 cases. Int J Gynecol Pathol 33:176–185PubMedCrossRefPubMedCentralGoogle Scholar
  152. Kim J, Coffey DM, Creighton CJ et al (2012) High-grade serous ovarian cancer arises from fallopian tube in a mouse model. PNAS 109:3921–3926PubMedCrossRefGoogle Scholar
  153. Kim HS, Kim TH, Chung HH, Song YS (2014) Risk and prognosis of ovarian cancer in women with endometriosis: a meta-analysis. Br J Cancer 110:1878–1890PubMedPubMedCentralCrossRefGoogle Scholar
  154. Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B (2011) Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A 108:9530–9535PubMedPubMedCentralCrossRefGoogle Scholar
  155. Kleppe M, Wang T, Van Gorp T, Slangen BFM, Kruse AJ, Kruitwagen RFPM (2011) Lymph node metastasis in stages I and II ovarian cancer: a review. Gynecol Oncol 123:610–614PubMedCrossRefGoogle Scholar
  156. Kobayashi H, Simimoto K, Moniwa N et al (2007) Risk of developing ovarian cancer among women with ovarian endometrioma: a cohort study in Shizuoka, Japan. Int J Gynecol Cancer 17:37–43PubMedCrossRefGoogle Scholar
  157. Kobel M, Kalloger SE, Huntsman DG et al (2010a) Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol 29:203–211PubMedCrossRefGoogle Scholar
  158. Kobel M, Kalloger SE, Santos JL, Huntsman DG, Gilks CB, Swenerton KD (2010b) Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications. Gynecol Oncol 116:50–56PubMedCrossRefGoogle Scholar
  159. Kobel M, Bak J, Bertelsen BI et al (2014) Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry. Histopathology 64:1004–1013PubMedCrossRefGoogle Scholar
  160. Kommoss S, Gilks CB, du Bois A, Kommoss F (2016) Ovarian carcinoma diagnosis: the clinical impact of 15 years of change. Br J Cancer 115:993–999PubMedPubMedCentralCrossRefGoogle Scholar
  161. Kondi-Pafiti A, Kairi-Vassilatou E, Iavazzo C et al (2012) Clinicopathologic features and immunoprofile of 30 cases of Brenner ovarian tumors. Arch Gynecol Obstet 285:1699–1702PubMedCrossRefPubMedCentralGoogle Scholar
  162. Koskas M, Uzan C, Gouy S et al (2011) Prognostic factors of a large retrospective series of mucinous borderline tumors of the ovary (excluding peritoneal pseudomyxoma). Ann Surg Oncol 18:40–48PubMedCrossRefPubMedCentralGoogle Scholar
  163. Kotsopoulos J, Rosen B, Fan I et al (2016) Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status. Gynecol Oncol 140:42–47PubMedCrossRefPubMedCentralGoogle Scholar
  164. Kraus J, Seidman JD (2010) The relationship between papillary infarction and microinvasion in ovarian atypical proliferative (“borderline”) serous and seromucinous tumors. Int J Gynecol Pathol 29:303–309PubMedCrossRefPubMedCentralGoogle Scholar
  165. Kroeger PT, Drapkin R (2017) Pathogenesis and heterogeneity of ovarian cancer. Curr Opin Obstet Gynecol 29:26–34PubMedCrossRefPubMedCentralGoogle Scholar
  166. Kuchenbaecker KB, Hopper JL, Barnes DR et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317:2402–2416PubMedCrossRefPubMedCentralGoogle Scholar
  167. Kuhn E, Kurman RJ, Shih I-M (2012a) Ovarian cancer is an imported disease: fact or fiction. Curr Obstet Gynecol Rep 1:1–9PubMedPubMedCentralCrossRefGoogle Scholar
  168. Kuhn E, Kurman RJ, Vang R et al (2012b) TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high grade serous carcinoma- evidence supporting the clonal relationship of the two lesions. J Pathol 226:421–426PubMedCrossRefPubMedCentralGoogle Scholar
  169. Kuhn E, Ayhan A, Shih IM, Seidman JD, Kurman RJ (2013) Ovarian Brenner tumour: a morphologic and immunohistochemical analysis suggesting an origin from fallopian tube epithelium. Eur J Cancer 49:3839–3849PubMedCrossRefPubMedCentralGoogle Scholar
  170. Kumar A, Le N, Tinker AV, Santos JL, Parsons C, Hoskins PJ (2014) Early-stage endometrioid ovarian carcinoma: population-based outcomes in British Columbia. Int J Gynecol Cancer 24:1401–1405PubMedCrossRefGoogle Scholar
  171. Kuo KT, Guan B, Feng Y et al (2009) Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res 69:4036–4042PubMedPubMedCentralCrossRefGoogle Scholar
  172. Kurman RJ, Shih IM (2016a) The dualistic model of ovarian carcinogenesis: revisited, revised and expanded. Am J Pathol 186:733–747PubMedPubMedCentralCrossRefGoogle Scholar
  173. Kurman RJ, Shih IM (2016b) Seromucinous tumors of the ovary: what’s in a name? Int J Gynecol Pathol 35:78–81PubMedPubMedCentralCrossRefGoogle Scholar
  174. Kurman RJ, Vang R, Junge J et al (2011) Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis. Am J Surg Pathol 35:1605–1614PubMedPubMedCentralCrossRefGoogle Scholar
  175. Kurman RJ, Carcangiu ML, Herrington CS, Young RH (eds) (2014) WHO classification of tumours of female reproductive organs. International Agency for Research on Cancer (IARC), LyonGoogle Scholar
  176. Labidi-Galy SI, Papp E, Hallberg D, Niknafs N, Adleff V, Noe M (2017) High grade serous ovarian carcinomas originate in the fallopian tube. Nat Commun 8:1093PubMedPubMedCentralCrossRefGoogle Scholar
  177. Lawrie TA, Winter-Roach BA, Heus P, Kitchener HC (2015) Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev 2015(12):CD004706. Scholar
  178. Ledermann JA, Luvero D, Shafer A et al (2014) Gynecologic Cancer Intergroup (GCIG) consensus review for mucinous ovarian carcinoma. Int J Gynecol Cancer 24(9 Suppl 3):S14–S19PubMedCrossRefGoogle Scholar
  179. Ledermann JA, Harter P, Gourley C et al (2016) Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol 17:1579–1589CrossRefGoogle Scholar
  180. Lee KR, Scully RE (2000) Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with ‘pseudomyxoma peritonei. Am J Surg Pathol 24:1447–1464PubMedCrossRefGoogle Scholar
  181. Lee Y, Miron A, Drapkin R et al (2007) A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 211:26–35PubMedCrossRefGoogle Scholar
  182. Lee Y-Y, Kim T-J, Kim M-J et al (2011) Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: a meta-analysis. Gynecol Oncol 122:541–547PubMedCrossRefGoogle Scholar
  183. Lee JY, Jeon I, Kim JW et al (2013a) Diabetes mellitus and ovarian cancer risk: a systematic review and meta-analysis of observational studies. Int J Gynecol Cancer 23:402–412PubMedCrossRefGoogle Scholar
  184. Lee S, Nelson G, Duan Q, Magliocco AM, Duggan MA (2013b) Precursor lesions and prognostic factors in primary peritoneal serous carcinoma. Int J Gynecol Pathol 32:547–555PubMedCrossRefGoogle Scholar
  185. Lee JY, Chung YS, Na K et al (2017) External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. J Gynecol Oncol 28:e73PubMedPubMedCentralCrossRefGoogle Scholar
  186. Leonhardt K, Einenkel J, Sohr S et al (2011) P53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary. Int J Gynecol Pathol 30:417–424PubMedCrossRefGoogle Scholar
  187. Licaj I, Jacobsen BK, Selmer RM, Maskarinec G, Weiderpass E, Gram IT (2017) Smoking and risk of ovarian cancer by histological subtypes: an analysis among 300,000 Norwegian women. Br J Cancer 116:270–276PubMedCrossRefGoogle Scholar
  188. Lim D, Ip PPC, Cheung ANY, Kiyokawa T, Oliva E (2015) Immunohistochemical comparison of ovarian and uterine endometrioid carcinoma, endometrioid carcinoma with clear cell change, and clear cell carcinoma. Am J Surg Pathol 39:1061–1069PubMedCrossRefGoogle Scholar
  189. Lim D, Murali R, Murray MP, Veras E, Park KJ, Soslow RA (2016) Morphological and immunohistochemical reevaluation of tumors initially diagnosed as ovarian endometrioid carcinoma with emphasis on high-grade tumors. Am J Surg Pathol 40:302–312PubMedPubMedCentralCrossRefGoogle Scholar
  190. Lin SF, Gerry E, Shih IM (2017) Tubal origin of ovarian cancer- the double-edged sword of haemoglobin. J Pathol 242:3–6PubMedCrossRefGoogle Scholar
  191. Lu CH, Chen IH, Chen YJ et al (2014) Primary treatment and prognostic factors of carcinosarcoma of the ovary, fallopian tube, and peritoneum: a Taiwanese Gynecologic Oncology Group study. Int J Gynecol Cancer 24:506–512PubMedCrossRefGoogle Scholar
  192. Mackay HJ, Brady MF, Oza AM et al (2010) Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer 20:945–952PubMedCrossRefGoogle Scholar
  193. Mackenzie R, Kommoss S, Winterhoff BJ et al (2015a) Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms. BMC Cancer 15:415PubMedPubMedCentralCrossRefGoogle Scholar
  194. Mackenzie R, Talhouk A, Eshragh S et al (2015b) Morphologic and molecular characteristics of mixed epithelial ovarian cancers. Am J Surg Pathol 39:1548–1557PubMedPubMedCentralCrossRefGoogle Scholar
  195. Magazzino F, Katsaros D, Ottaiano A et al (2011) Surgical and medical treatment of clear cell ovarian cancer: results from the multicenter Italian trials in ovarian cancer (MITO) 9 retrospective study. Int J Gynecol Cancer 21:1063–1070PubMedCrossRefGoogle Scholar
  196. Mahdi H, Moslemi-Kebria M, Levinson KL et al (2013) Prevalence and prognostic impact of lymphadenectomy and lymph node metastasis in clinically early-stage ovarian clear cell carcinoma. Int J Gynecol Cancer 23:1226–1230PubMedCrossRefGoogle Scholar
  197. Majd HS, Ferrari F, Manek S et al (2016) Diaphragmatic peritonectomy vs. full thickness resection with pleurectomy during visceral peritoneal debulking (VPD) in 100 consecutive patients with stage IIIC–IV ovarian cancer: a surgical-histological analysis. Gynecol Oncol 140:430–435CrossRefGoogle Scholar
  198. Malpica A, Deavers MT, Lu K et al (2004) Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 28:496–504PubMedCrossRefGoogle Scholar
  199. Maniar KP, Wang Y, Visvanathan K, Shih I-M, Kurman RJ (2014) Evaluation of microinvasion and lymph node involvement in ovarian serous borderline/atypical proliferative serous tumors: a morphologic and immunohistochemical analysis of 37 cases. Am J Surg Pathol 38:743–755PubMedPubMedCentralCrossRefGoogle Scholar
  200. Mao TL, Shih IM (2013) The roles of ARID1A in gynecologic cancer. J Gynecol Oncol 24:376–381PubMedPubMedCentralCrossRefGoogle Scholar
  201. Marchetti C, Ferrandina G, Cormio G et al (2016) Brain metastases in patients with EOC: clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19). Gynecol Oncol 143:532–538PubMedCrossRefGoogle Scholar
  202. Maritschnegg E, Wang Y, Pecha N et al (2015) Lavage of the uterine cavity for molecular detection of müllerian duct carcinomas: a proof-of-concept study. J Clin Oncol 33:4293–4300PubMedPubMedCentralCrossRefGoogle Scholar
  203. Marquez RT, Baggerly KA, Patterson AP et al (2005) Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res 11:6116–6126PubMedCrossRefGoogle Scholar
  204. Matsuno RK, Sherman ME, Visvanathan K et al (2013) Agreement for tumor grade of ovarian carcinoma: analysis of archival tissues from the surveillance, epidemiology, and end results residual tissue repository. Cancer Causes Control 24:749–757PubMedPubMedCentralCrossRefGoogle Scholar
  205. Matsuura Y, Robertson G, Marsden DE et al (2007) Thromboembolic complications in patients with clear cell carcinoma of the ovary. Gynecol Oncol 104:406–410PubMedCrossRefPubMedCentralGoogle Scholar
  206. McCluggage WG, Judge MJ, Clarke BA et al (2015) Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Mod Pathol 28:1101–1122PubMedCrossRefGoogle Scholar
  207. McDaniel AS, Stall JN, Hovelson DH et al (2015) Next-generation sequencing of tubal intraepithelial carcinomas. JAMA Oncol 1:1128–1132PubMedPubMedCentralCrossRefGoogle Scholar
  208. McGuire V, Hartge P, Liao LM et al (2016) Parity and oral contraceptive use in relation to ovarian cancer risk in older women. Cancer Epidemiol Biomark Prev 25:1059–1063CrossRefGoogle Scholar
  209. McKenney JK, Balzer BL, Longacre TA (2006a) Lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors): pathology, prognosis and proposed classification. Am J Surg Pathol 30:614–624PubMedCrossRefPubMedCentralGoogle Scholar
  210. McKenney JK, Balzer BL, Longacre TA (2006b) Patterns of ovarian stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a re-evaluation of the concept of stromal microinvasion. Am J Surg Pathol 30:1209–1221PubMedCrossRefPubMedCentralGoogle Scholar
  211. McKenney JK, Soslow RA, Longacre TA (2008) Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei. Am J Surg Pathol 32:645–655PubMedCrossRefGoogle Scholar
  212. McKenney JK, Gilks CB, Kalloger S, Longacre TA (2016) Classification of extraovarian implants in patients with ovarian serous borderline tumors (tumors of low malignant potential) based on clinical outcome. Am J Surg Pathol 40:1155–1164PubMedCrossRefPubMedCentralGoogle Scholar
  213. Meriden Z, Yemelyanova AV, Vang R, Ronnett BM (2011) Ovarian metastases of pancreaticobiliary tract adenocarcinomas: analysis of 35 cases, with emphasis on the ability of metastases to simulate primary ovarian mucinous tumors. Am J Surg Pathol 35:276–288PubMedCrossRefGoogle Scholar
  214. Merritt MA, Green AC, Nagle CM, Webb PM (2008) Australian Cancer Study (Ovarian Cancer); Australian Ovarian Cancer Study Group. Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 122:170–176PubMedCrossRefGoogle Scholar
  215. Mesbah Ardakani N, Giardina T, Amanuel B, Stewart CJ (2017) Molecular profiling reveals a clonal relationship between ovarian mucinous tumors and corresponding mural carcinomatous nodules. Am J Surg Pathol 41:1261–1266PubMedCrossRefGoogle Scholar
  216. Mink PJ, Sherman ME, Devesa SS (2002) Incidence patterns of invasive and borderline ovarian tumors among white women and black women in the United States: results from the SEER program 1978–1998. Cancer 95:2380–2389PubMedCrossRefGoogle Scholar
  217. Mirza MR, Monk BJ, Herrstedt J et al (2016) Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 375:2154–2164CrossRefGoogle Scholar
  218. Moorman PG, Havrilesky LJ, Gierisch JM et al (2013) Oral contraceptives and risk of ovarian cancer and breast cancer among high risk women: a systematic review and meta-analysis. J Clin Oncol 31:4188–4198PubMedCrossRefGoogle Scholar
  219. Morency E, Leitao MM, Soslow RA (2016) Low-stage high-grade serous ovarian carcinomas: support for an extraovarian origin. Int J Gynecol Pathol 35:222–229PubMedPubMedCentralCrossRefGoogle Scholar
  220. Morrison JC, Blanco LZ, Vang R, Ronnett BM (2015) Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting: analysis of a case series. Am J Surg Pathol 39:442–453PubMedCrossRefGoogle Scholar
  221. Mueller JJ, Holzapfel M, Han CH et al (2016) Staging lymphadenectomy in patients with clear cell carcinoma of the ovary. Int J Gynecol Cancer 26:120–124PubMedPubMedCentralCrossRefGoogle Scholar
  222. Murakami R, Matsamura N, Brown JB et al (2017) Exome sequencing landscape analysis in ovarian clear cell carcinoma shed light on key chromosomal regions and mutation gene networks. Am J Pathol 187:2246–2258PubMedCrossRefGoogle Scholar
  223. Nagle CM, Francis JE, Nelson AE et al (2011) Reducing time to diagnosis does not improve outcomes for women with symptomatic ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 29:2253–2258PubMedCrossRefGoogle Scholar
  224. Narod S (2016) Can advanced stage ovarian cancer be cured? Nat Rev Clin Oncol 13:255–261PubMedCrossRefGoogle Scholar
  225. Nasioudis D, Sisti G, Kanninen TT et al (2016a) Epidemiology and outcomes of squamous ovarian carcinoma; a population-based study. Gynecol Oncol 141:128–133PubMedCrossRefGoogle Scholar
  226. Nasioudis D, Sisti G, Kanninen TT, Fambrini M, DiTommaso M (2016b) Prognostic significance of transitional cell carcinoma-like morphology of high grade serous ovarian carcinoma: a comparative study. Int J Gynecol Cancer 26:1624–1629PubMedCrossRefGoogle Scholar
  227. Nasioudis D, Chapman-Davis E, Frey MK, Caputo TA, Witkin SS, Holcomb K (2017a) Should epithelial ovarian carcinoma metastatic to the inguinal lymph nodes be assigned stage IVB? Gynecol Oncol 147:81–84PubMedCrossRefGoogle Scholar
  228. Nasioudis D, Chapman-Davis E, Witkin SS, Holcomb K (2017b) Prognostic significance of lymphadenectomy and prevalence of lymph node metastasis in clinically-apparent stage I endometrioid and mucinous ovarian carcinoma. Gynecol Oncol 144:414–419PubMedCrossRefGoogle Scholar
  229. National Academies of Sciences, Engineering and Medicine (2016) Ovarian cancers: evolving paradigms in research and care. National Academies Press, Washington, DC. 2017CrossRefGoogle Scholar
  230. NHMRC (National Health and Medical Research Council) (n.d.) Australian Government. Accessed 6 Oct 2008
  231. Okoye E, Euscher ED, Malpica A (2016) Ovarian low-grade serous carcinoma: a clinicopathologic study of 33 cases with primary surgery performed at a single institution. Am J Surg Pathol 40:627–635PubMedCrossRefGoogle Scholar
  232. Oliver KE, Brady WE, Birrer M et al (2017) An evaluation of progression-free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: an NRG Oncology/Gynecologic Oncology Group experience. Gynecol Oncol 147:243–249PubMedCrossRefGoogle Scholar
  233. Oseledchyk A, Leitao MM, Konner J et al (2017) Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a surveillance, epidemiology, and end results cohort study, 2000–2013. Ann Oncol 28:2985–2993PubMedCrossRefGoogle Scholar
  234. Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2 (2016) No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol 141:386–401CrossRefGoogle Scholar
  235. Ovarian Tumor Tissue Analysis (OTTA) Consortium (2017) Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer. JAMA Oncol 3:e173290CrossRefGoogle Scholar
  236. Paik ES, Shim M, Choi HJ et al (2016) Impact of lymphadenectomy on survival after recurrence in patients with advanced ovarian cancer without suspected lymph node metastasis. Gynecol Oncol 143:252–257PubMedCrossRefGoogle Scholar
  237. Paleari L, Gandini S, Provinciali N, Puntoni M, Colombo N, DeCensi A (2017) Clinical benefit and risk of death with endocrine therapy in ovarian cancer: a comprehensive review and meta-analysis. Gynecol Oncol 146:504–513PubMedCrossRefGoogle Scholar
  238. Park HK, Ruterbusch JJ, Cote ML (2017) Recent trends in ovarian cancer incidence and relative survival in the Unites States by race/ethnicity and histologic subtypes. Cancer Epidemiol Biomark Prev 26:1511–1518CrossRefGoogle Scholar
  239. Parker WH, Feskanich D, Broder MS et al (2013) Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses’ health study. Obstet Gynecol 121:709–716PubMedPubMedCentralCrossRefGoogle Scholar
  240. Patch AM, Christie EL, Etemadmoghadam D et al (2015) Whole-genome characterization of chemoresistant ovarian cancer. Nature 521:489–494PubMedCrossRefGoogle Scholar
  241. Pearce CL, Templeman C, Rossing MA et al (2012) Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 13:385–394PubMedPubMedCentralCrossRefGoogle Scholar
  242. Pennington KP, Walsh T, Harrell MI et al (2014) Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 20:764–775PubMedCrossRefGoogle Scholar
  243. Perets R, Wyant GA, Muto KW et al (2013) Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell 24:751–765PubMedPubMedCentralCrossRefGoogle Scholar
  244. Petit T, Velten M, d’Hombres A et al (2007) Long-term survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy. Gynecol Oncol 104:104–108PubMedCrossRefGoogle Scholar
  245. Pinsky PF, Yu K, Kramer BS et al (2016) Extended mortality results for ovarian cancer screening in the PLCO trial with median 15 years follow-up. Gynecol Oncol 143:270–275PubMedPubMedCentralCrossRefGoogle Scholar
  246. Powell CB (2014) Risk reducing salpingo-oophorectomy for BRCA mutation carriers: twenty years later. Gynecol Oncol 132:261–263PubMedCrossRefPubMedCentralGoogle Scholar
  247. Powell CB, Swisher EM, Cass I et al (2013) Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy. Gynecol Oncol 129:364–371PubMedCrossRefGoogle Scholar
  248. Powless CA, Aletti GD, Bakkum-Gamez JN, Cliby WA (2011) Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: implications for surgical staging. Gynecol Oncol 122:536–540PubMedCrossRefGoogle Scholar
  249. Prat J, FIGO committee on gynecologic oncology (2015) Abridged republication of FIGO’s staging classification for cancer of the ovary, fallopian tube, and peritoneum. Cancer 121:3452–3454PubMedCrossRefPubMedCentralGoogle Scholar
  250. Provenza C, Young RH, Prat J (2008) Anaplastic carcinoma in mucinous ovarian tumors: a clinicopathologic study of 34 cases emphasizing the crucial impact of stage on prognosis, their histologic spectrum, and overlap with sarcomalike mural nodules. Am J Surg Pathol 32:383–389PubMedCrossRefPubMedCentralGoogle Scholar
  251. Qian XQ, Hua XP, Wu JH et al (2018) Clinical predictors of recurrence and prognostic value of lymph node involvement in the serous borderline ovarian tumor. Int J Gynecol Cancer 28:279–284PubMedCrossRefPubMedCentralGoogle Scholar
  252. Rabban JT, Garg K, Crawford B, Chen LM, Zaloudek CJ (2014) Early detection of high-grade tubal serous carcinoma in women at low risk for hereditary breast and ovarian cancer syndrome by systematic examination of fallopian tubes incidentally removed during benign surgery. Am J Surg Pathol 38:729–742PubMedCrossRefPubMedCentralGoogle Scholar
  253. Rabban JT, Vohra P, Zaloudek CJ (2015) Nongynecologic metastases to fallopian tube mucosa: a potential mimic of tubal high-grade serous carcinoma and benign tubal mucinous metaplasia or nonmucinous hyperplasia. Am J Surg Pathol 39:35–51PubMedCrossRefGoogle Scholar
  254. Rambau PF, Duggan MA, Ghatage P et al (2016) Significant frequency of MSH2/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype-specific Lynch syndrome screening in ovarian carcinomas. Histopathology 69:288–297PubMedCrossRefGoogle Scholar
  255. Rambau PF, McIntyre JB, Taylor J et al (2017) Morphologic reproducibility, genotyping, and immunohistochemical profiling do not support a category of seromucinous carcinoma of the ovary. Am J Surg Pathol 41:685–695PubMedCrossRefPubMedCentralGoogle Scholar
  256. Rasmussen CB, Jensen A, Albieri V, Andersen KK, Kjaer SK (2017a) Is pelvic inflammatory disease a risk factor for ovarian cancer? Cancer Epidemiol Biomark Prev 26:104–109CrossRefGoogle Scholar
  257. Rasmussen CB, Kjaer SK, Albieri V et al (2017b) Pelvic inflammatory disease and the risk of ovarian cancer and borderline ovarian tumors: a pooled analysis of 13 case-control studies. Am J Epidemiol 185:8–20PubMedCrossRefPubMedCentralGoogle Scholar
  258. Rasmussen ELK, Hannibal CG, Dehlendorff C et al (2017c) Parity, infertility, oral contraceptives, and hormone replacement therapy and the risk of ovarian serous borderline tumors: a nationwide case-control study. Gynecol Oncol 144:571–576PubMedCrossRefPubMedCentralGoogle Scholar
  259. Rauh-Hain JA, Diver EJ, Clemmer JT et al (2013) Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis. Gynecol Oncol 131:46–51PubMedCrossRefPubMedCentralGoogle Scholar
  260. Rauh-Hain JA, Gonzales R, Bregar AJ et al (2016) Patterns of care, predictors and outcomes of chemotherapy for ovarian carcinosarcoma: a National Cancer Database analysis. Gynecol Oncol 142:38–43PubMedCrossRefGoogle Scholar
  261. Reigstad MM, Storeng R, Myklebust TA et al (2017) Cancer risk in women treated with fertility drugs according to parity status: a registry-based cohort study. Cancer Epidemiol Biomark Prev 26:1–10CrossRefGoogle Scholar
  262. Reyes MC, Arnold AG, Kauff ND, Levine DA, Soslow RA (2014) Invasion patterns of metastatic high grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency. Mod Pathol 27:1405–1411PubMedCrossRefGoogle Scholar
  263. Riopel MA, Ronnett BM, Kurman RJ (1999) Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors: atypical proliferative (borderline) tumors, and intraepithelial, microinvasive, invasive and metastatic carcinomas. Am J Surg Pathol 23:617–635PubMedCrossRefGoogle Scholar
  264. Ritterhouse LL, Nowak JA, Strickland KC et al (2016) Morphologic correlates of molecular alterations in extrauterine Mullerian carcinomas. Mod Pathol 29:893–903PubMedCrossRefPubMedCentralGoogle Scholar
  265. Rodriguez IM, Prat J (2002) Mucinous tumors of the ovary: a clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas. Am J Surg Pathol 26:139–152PubMedCrossRefGoogle Scholar
  266. Rodriguez IM, Irving JA, Prat J (2004) Endocervical-like mucinous borderline tumors of the ovary: a clinicopathologic analysis of 31 cases. Am J Surg Pathol 28:1311–1318PubMedCrossRefPubMedCentralGoogle Scholar
  267. Roelofsen T, van Kempen LCLT, van der Laak JAWM, van Ham MA, Bulten J, Massuger LFAG (2012) Concurrent endometrial intraepithelial carcinoma (EIC) and serous ovarian cancer: can EIC be seen as the precursor lesion? Int J Gynecol Cancer 22:457–464PubMedCrossRefPubMedCentralGoogle Scholar
  268. Roma AA, Masand RP (2014) Ovarian Brenner tumors and Walthard nests: a histologic and immunohistochemical study. Hum Pathol 45:2417–2422PubMedCrossRefGoogle Scholar
  269. Roma AA, Masand PR (2015) Different staining patterns of ovarian Brenner tumor and the associated mucinous tumor. Ann Diagn Pathol 19:29–32PubMedCrossRefGoogle Scholar
  270. Ronnett BM, Seidman JD (2003) Mucinous tumors arising in ovarian mature cystic teratomas: relationship to the clinical syndrome of pseudomyxoma peritonei. Am J Surg Pathol 27:650–657PubMedCrossRefGoogle Scholar
  271. Ronnett BM, Kurman RJ, Zahn CM (1995a) Pseudomyxoma peritonei in women: a clinicopathologic analysis of 30 cases with emphasis on site of origin, prognosis, and relationship to ovarian mucinous tumors of low malignant potential. Hum Pathol 26:509–524PubMedCrossRefGoogle Scholar
  272. Ronnett BM, Zahn CM, Kurman RJ (1995b) Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis: a clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to “pseudomyxoma peritonei”. Am J Surg Pathol 19:1390–1408PubMedCrossRefGoogle Scholar
  273. Ronnett BM, Shmookler BM, Diener-West M, Sugarbaker PH, Kurman RJ (1997) Immunohistochemical evidence supporting the appendiceal origin of pseudomyxoma peritonei in women. Int J Gynecol Pathol 16:1–9PubMedCrossRefGoogle Scholar
  274. Ronnett BM, Yan H, Kurman RJ et al (2001) Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer 92:85–91PubMedCrossRefGoogle Scholar
  275. Ronnett BM, Kajdacsy-Balla A, Gilks CB et al (2004) Mucinous borderline ovarian tumors: points of general agreement and persistent controversies regarding nomenclature, diagnostic criteria, and behavior. Hum Pathol 35:949–960PubMedCrossRefPubMedCentralGoogle Scholar
  276. Roth LM, Emerson RE, Ulbright TM (2003) Ovarian endometrioid tumors of low malignant potential: a clinicopathologic study of 30 cases with comparison to well-differentiated endometrioid adenocarcinoma. Am J Surg Pathol 27:1253–1259PubMedCrossRefPubMedCentralGoogle Scholar
  277. Rudaitis V, Zvirblis T, Kanopiene D et al (2014) BRCA1/2 mutation status is an independent factor of improved survival for advanced (stage III–IV) ovarian cancer. Int J Gynecol Cancer 24:1395–1400PubMedCrossRefPubMedCentralGoogle Scholar
  278. Rungruang BJ, Miller A, Krivak TC et al (2017) What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study. Cancer 123:985–993PubMedCrossRefPubMedCentralGoogle Scholar
  279. Rustin GJS, van der Burg MEL, Griffin CL et al (2010) Early versus delayed treatment of relapsed ovarian cancer (MRC OVO5/EORTC55955): a randomized trial. Lancet 376:1155–1163PubMedCrossRefPubMedCentralGoogle Scholar
  280. Ryan NAJ, Evans DG, Green K, Crosbie EJ (2017) Pathological features and clinical behavior of Lynch syndrome-associated ovarian cancer. Gynecol Oncol 144:491–495PubMedPubMedCentralCrossRefGoogle Scholar
  281. Ryland GL, Hunter SM, Doyle MA et al (2015) Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors. Genome Med 7:87PubMedPubMedCentralCrossRefGoogle Scholar
  282. Said I, Bohm S, Beasley J et al (2017) The chemotherapy response score (CRS): interobserver reproducibility in a simple and prognostically relevant system for reporting the histologic response to neoadjuvant chemotherapy in tuboovarian high-grade serous carcinoma. Int J Gynecol Pathol 36:172–179PubMedPubMedCentralGoogle Scholar
  283. Salvador S, Gilks B, Kobel M, Huntsman D, Rosen B, Miller D (2009) The fallopian tube: primary site of most pelvic high-grade serous carcinomas. Int J Gynecol Cancer 19:58–64PubMedCrossRefPubMedCentralGoogle Scholar
  284. Sangoi AR, McKenney JK, Dadras SS et al (2008) Lymphatic vascular invasion in ovarian serous tumors of low malignant potential with stromal microinvasion: a case-control study. Am J Surg Pathol 32:261–268PubMedCrossRefPubMedCentralGoogle Scholar
  285. Sato N, Tsunoda H, Nishida M (2000) Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 60:7052–7056PubMedPubMedCentralGoogle Scholar
  286. Schmoeckel E, Odai-Afotey AA, Schleiβheimer M et al (2017) LEF1 is preferentially expressed in the tubal-peritoneal junctions and is a reliable marker of tubal intraepithelial lesions. Mod Pathol 30:1241–1250PubMedPubMedCentralCrossRefGoogle Scholar
  287. Schultheis AM, Ng CKY, De Filippo MR et al (2016) Massively parallel sequencing-based clonality analysis of synchronous endometrioid endometrial and ovarian carcinomas. J Natl Cancer Inst 108:djv427PubMedPubMedCentralCrossRefGoogle Scholar
  288. Seidman JD (1996) Prognostic importance of atypia and hyperplasia in endometriosis. Int J Gynecol Pathol 15:1–9PubMedCrossRefGoogle Scholar
  289. Seidman JD (2013) The presence of mucosal iron in the fallopian tube supports the “incessant menstruation hypothesis” for ovarian carcinoma. Int J Gynecol Pathol 32:454–458PubMedCrossRefGoogle Scholar
  290. Seidman JD (2015) Serous tubal intraepithelial carcinoma localizes to the tubal-peritoneal junction: a pivotal clue to the site of origin of extrauterine high grade serous carcinoma (ovarian cancer). Int J Gynecol Pathol 34:112–120PubMedCrossRefGoogle Scholar
  291. Seidman JD, Khedmati F (2008) Exploring the histogenesis of ovarian mucinous and transitional cell (Brenner) neoplasms and their relationship with Walthard cell nests: a study of 120 tumors. Arch Pathol Lab Med 132:1753–1760PubMedGoogle Scholar
  292. Seidman JD, Krishnan J (2016) Non-neoplastic conditions of the ovaries in grossly normal adnexa: a clinicopathologic study of 403 completely embedded cases. Int J Gynecol Pathol 35:544–548PubMedCrossRefGoogle Scholar
  293. Seidman JD, Kurman RJ (2000) Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol 31:539–557PubMedCrossRefGoogle Scholar
  294. Seidman JD, Wang BG (2007) Evaluation of normal sized ovaries associated with primary peritoneal serous carcinoma for possible precursors of ovarian serous carcinoma. Gynecol Oncol 106:201–206PubMedCrossRefGoogle Scholar
  295. Seidman JD, Sherman ME, Bell KA et al (2002) Salpingitis, salpingoliths and serous tumors of the ovary: is there a connection? Int J Gynecol Pathol 21:101–107PubMedCrossRefGoogle Scholar
  296. Seidman JD, Kurman RJ, Ronnett BM (2003) Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol 27:985–993PubMedCrossRefGoogle Scholar
  297. Seidman JD, Soslow RA, Vang R et al (2004) Borderline ovarian tumors: diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images. Hum Pathol 35:918–933PubMedCrossRefGoogle Scholar
  298. Seidman JD, Cosin JA, Wang BG et al (2010a) Upstaging pathologic stage I ovarian carcinoma based on dense adhesions is not warranted: a clinicopathologic study of 84 patients originally classified as FIGO stage II. Gynecol Oncol 119:250–254PubMedCrossRefGoogle Scholar
  299. Seidman JD, Yemelyanova AV, Khedmati F et al (2010b) Prognostic factors for stage I ovarian carcinoma. Int J Gynecol Pathol 29:1–7PubMedCrossRefGoogle Scholar
  300. Seidman JD, Yemelyanova A, Zaino RJ et al (2011a) The tubal-peritoneal junction: a potential site of carcinogenesis. Int J Gynecol Pathol 30:4–11PubMedCrossRefGoogle Scholar
  301. Seidman JD, Zhao P, Yemelyanova A (2011b) “Primary peritoneal” high grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer. Gynecol Oncol 120:470–473PubMedCrossRefGoogle Scholar
  302. Seidman JD, Yemelyanova A, Cosin JA et al (2012) Survival rates for FIGO stage III ovarian carcinoma by cell type: a study of 262 unselected patients with uniform pathologic review. Int J Gynecol Cancer 22:367–371PubMedCrossRefGoogle Scholar
  303. Seidman JD, Vang R, Ronnett BM, Yemelyanova A, Cosin JA (2015) Distribution and case-fatality ratios by cell type for ovarian carcinomas: a 22-year series of 562 patients with uniform current histological classification. Gynecol Oncol 136:336–340PubMedCrossRefGoogle Scholar
  304. Seidman JD, Krishnan J, Yemelyanova A, Vang R (2016) Incidental serous tubal intraepithelial carcinoma and non-neoplastic conditions of the fallopian tubes in grossly normal adnexa: a clinicopathologic study of 388 completely embedded cases. Int J Gynecol Pathol 35:423–429PubMedCrossRefGoogle Scholar
  305. Seidman JD, Savage J, Yemelyanova A, Vang R, Kurman RJ (Submitted) Intratumoral heterogeneity accounts for apparent progression of noninvasive serous tumors to low-grade serous carcinoma: a study of 30 low-grade serous tumors of the ovary associated with peritoneal carcinomatosisGoogle Scholar
  306. Shappell HW, Riopel MA, Smith-Sehdev A et al (2002) Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive and invasive carcinoma. Am J Surg Pathol 26:1529–1541PubMedCrossRefGoogle Scholar
  307. Shazly SAM, Laughlin-Tommaso SK, Dowdy SC, Famuyide AO (2016) Staging for low malignant potential ovarian tumors: a global perspective. Am J Obstet Gynecol 215:153–168PubMedCrossRefGoogle Scholar
  308. Sherman ME, Guido R, Wentzensen N, Yang HP, Mai PI, Greene MH (2012) New views on the pathogenesis of high-grade pelvic serous carcinoma with suggestions for advancing future research. Gynecol Oncol 127:645–650PubMedPubMedCentralCrossRefGoogle Scholar
  309. Sherman ME, Piedmonte M, Mai PL et al (2014) Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. J Clin Oncol 32:3275–3283PubMedPubMedCentralCrossRefGoogle Scholar
  310. Shim SH, Kim SN, Jung PS, Dong M, Kim JE, Lee SJ (2016) Impact of surgical staging on prognosis in patients with borderline ovarian tumours: a meta-analysis. Eur J Cancer 54:84–95PubMedCrossRefGoogle Scholar
  311. Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67:7–30CrossRefGoogle Scholar
  312. Sieh W, Salvador S, McGuire V et al (2013) Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. Int J Epidemiol 42:579–589PubMedPubMedCentralCrossRefGoogle Scholar
  313. Simons M, Ezendam N, Bulten J, Naqteqaal I, Massuger L (2015) Survival of patients with mucinous ovarian carcinoma and ovarian metastases: a population-based cancer registry study. Int J Gynecol Cancer 25:1208–1215PubMedCrossRefGoogle Scholar
  314. Simons M, Massuger L, Bruls J, Bulten J, Teerenstra S, Naqteqaal I (2017) Relatively poor survival of mucinous ovarian carcinoma in advanced stage: a systematic review and meta-analysis. Int J Gynecol Cancer 27:651–658PubMedCrossRefGoogle Scholar
  315. Singer G, Stohr R, Cope L et al (2005) Patterns of p53 mutations separate ovarian serous borderline tumors and low and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 29:218–224PubMedCrossRefGoogle Scholar
  316. Singh R, Cho KR (2017) Serous tubal intraepithelial carcinoma or not? metastases to fallopian tube mucosa can masquerade as in situ lesions. Arch Pathol Lab Med 141:1313–1315PubMedCrossRefGoogle Scholar
  317. Singh N, Gilks CB (2017) The changing landscape of gynaecological cancer diagnosis: implications for histopathological practice in the 21st century. Histopathology 70:56–69PubMedCrossRefGoogle Scholar
  318. Singh N, Gilks CB, Wilkinson N, McCluggage WG (2014) Assignment of primary site in high-grade serous tubal, ovarian and peritoneal carcinoma: a proposal. Histopathology 65:149–154PubMedCrossRefGoogle Scholar
  319. Singh N, Gilks CB, Wilkinson N, McCluggage WG (2015) The secondary Mullerian system, field effect, BRCA, and tubal fimbria: our evolving understanding of the origin of tubo-ovarian high-grade serous carcinoma and why assignment of primary site matters. Pathology 47:423–431PubMedCrossRefPubMedCentralGoogle Scholar
  320. Singh N, Gilks CB, Hirshowitz L, Wilkinson N, McCluggage WG (2016) Adopting a uniform approach to site assignment in tubo-ovarian high-grade serous carcinoma: the time has come. Int J Gynecol Pathol 35:230–237PubMedCrossRefPubMedCentralGoogle Scholar
  321. Singh P, Kaushal V, Rai B et al (2018) Chemotherapy response score is a useful histologic predictor of prognosis in high grade serous carcinoma. Histopathology 72:619–625PubMedCrossRefPubMedCentralGoogle Scholar
  322. Singh N, Benson JL, Gan C et al (2018) Disease distribution in low-stage tubo-ovarian high-grade serous carcinoma (HGSC): implications for assigning primary site and FIGO stage. Int J Gynecol Pathol. 37:324–30 Scholar
  323. Skates SJ, Greene MH, Buys SS et al (2017) Early detection of ovarian cancer using the risk of ovarian cancer algorithm with frequent CA125 testing in women at increased familial risk-combined results from two screening trials. Clin Cancer Res 23:3628–3637PubMedPubMedCentralCrossRefGoogle Scholar
  324. Song T, Kim MK, Kim ML et al (2017) Impact of opportunistic salpingectomy on anti-Mullerian hormone in patients undergoing laparoscopic hysterectomy: a multicenter randomized controlled trial. Br J Obstet Gynaecol 124:314–320CrossRefGoogle Scholar
  325. Soslow RA, Han G, Park KJ et al (2012) Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. Mod Pathol 25:625–636PubMedCrossRefGoogle Scholar
  326. Stewart CJR, Leung YC, Whitehouse A (2012) Fallopian tube metastases of non-gynaecological origin: a series of 20 cases emphasizing patterns of involvement including intra-epithelial spread. Histopathology 60:E106–E114PubMedCrossRefPubMedCentralGoogle Scholar
  327. Stewart CJR, Bowtell DDL, Doherty DA, Leung YC (2017) Long-term survival of patients with mismatch repair protein-deficient, high stage ovarian clear cell carcinoma. Histopathology 70:309–313PubMedCrossRefGoogle Scholar
  328. Storey DJ, Rush R, Stewart M et al (2008) Endometrioid epithelial ovarian cancer: 20 years of prospectively collected data from a single center. Cancer 112:2211–2220PubMedCrossRefPubMedCentralGoogle Scholar
  329. Suehiro Y, Sakamoto M, Umayahara K et al (2000) Genetic aberrations detected by comparative genomic hybridization in ovarian clear cell adenocarcinomas. Oncology 59:50–56PubMedCrossRefGoogle Scholar
  330. Suh DH, Park J-Y, Lee J-Y et al (2015) The clinical value of surgeons’ efforts of preventing intraoperative tumor rupture in stage I clear cell carcinoma of the ovary: a Korean multicenter study. Gynecol Oncol 137:412–417PubMedCrossRefGoogle Scholar
  331. Sung PL, Chang YH, Chao KC, Chuang CM et al (2014) Global distribution patterns of histological subtypes of epithelial ovarian cancer: a database analysis and systematic review. Gynecol Oncol 133:147–154PubMedCrossRefGoogle Scholar
  332. Surveillance, Epidemiology and End Results (SEER) (n.d.) National Cancer Institute. Accessed 13 Mar 2017
  333. Suzuki K, Takakura S, Saito M et al (2014) Impact of surgical staging in stage I clear cell adenocarcinoma of the ovary. Int J Gynecol Cancer 24:1181–1189PubMedCrossRefGoogle Scholar
  334. Swenerton KD, Santos JL, Gilks CB et al (2011) Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers. Ann Oncol 22:341–347PubMedCrossRefGoogle Scholar
  335. Szych C, Staebler A, Connolly DC, Wu R, Cho KR, Ronnett BM (1999) Molecular genetic evidence supporting the clonality and appendiceal origin of pseudomyxoma peritonei in women. Am J Pathol 154:1849–1855PubMedPubMedCentralCrossRefGoogle Scholar
  336. Tabrizi AD, Kalloger SE, Kobel M et al (2010) Primary ovarian mucinous carcinoma of intestinal type: significance of pattern of invasion and immunohistochemical expression profile in a series of 31 cases. Int J Gynecol Pathol 29:99–107PubMedCrossRefGoogle Scholar
  337. Tafe LJ, Muller KE, Ananda G et al (2016) Molecular genetic analysis of ovarian Brenner tumors and associated mucinous epithelial neoplasms: high variant concordance and identification of mutually exclusive RAS driver mutations and MYC amplification. Am J Pathol 186:671–677PubMedPubMedCentralCrossRefGoogle Scholar
  338. Takeuchi T, Ohishi Y, Imamura H et al (2013) Ovarian transitional cell carcinoma represents a poorly differentiated form of high-grade serous or endometrioid adenocarcinoma. Am J Surg Pathol 37:1091–1099PubMedCrossRefGoogle Scholar
  339. Tang S, Onuma K, Deb P et al (2012) Frequency of serous tubal intraepithelial carcinoma in various gynecologic malignancies: a study of 300 consecutive cases. Int J Gynecol Pathol 31:103–110PubMedCrossRefGoogle Scholar
  340. Tang S, Yang F, Du X, Lu Y, Zhang L, Zhou X (2016) Aberrant expression of anaplastic lymphoma kinase in ovarian carcinoma independent of gene rearrangement. Int J Gynecol Pathol 35:337–347PubMedCrossRefGoogle Scholar
  341. Taube ET, Denkert C, Sehouli J et al (2017) Cytokeratin 5/6 expression, prognosis, and association with estrogen receptor α in high-grade serous ovarian carcinoma. Hum Pathol 67:30–36PubMedCrossRefGoogle Scholar
  342. Taylor J, McCluggage WG (2015) Ovarian seromucinous carcinoma: report of a series of a newly categorized and uncommon neoplasm. Am J Surg Pathol 39:983–992PubMedCrossRefGoogle Scholar
  343. Temkin SM, Miller EA, Samimi G et al (2017) Outcomes from ovarian cancer screening in the PLCO trial: histologic heterogeneity impacts detection, overdiagnosis and survival. Eur J Cancer 87:182–188PubMedCrossRefGoogle Scholar
  344. The Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474:609–615PubMedCentralCrossRefPubMedGoogle Scholar
  345. Tolcher MC, Swisher EM, Medeiros F et al (2015) Characterization of precursor lesions in the endometrium and fallopian tube epithelium of early-stage uterine serous carcinoma. Int J Gynecol Pathol 34:57–64PubMedPubMedCentralCrossRefGoogle Scholar
  346. Tothill RW, Tinker AV, George J et al (2008) Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14:5198–5208PubMedCrossRefGoogle Scholar
  347. Trabert B, Ness RB, Lo-Ciganic WH et al (2014) Aspirin, non-aspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the ovarian cancer association consortium. J Natl Cancer Inst 106:djt431PubMedPubMedCentralCrossRefGoogle Scholar
  348. Trillsch F, Mahner S, Vettorazzi E et al (2015) Surgical staging and prognosis in serous borderline ovarian tumors (BOT): a subanalysis of the AGO ROBOT study. Br J Cancer 112:660–666PubMedPubMedCentralCrossRefGoogle Scholar
  349. Tsuda H, Ito YM, Ohashi Y et al (2005) Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinoma by cDNA microarray analyses. Clin Cancer Res 11:6880–6888PubMedCrossRefGoogle Scholar
  350. Tworoger SS, Gertig DM, Gates MA et al (2008) Caffeine, alcohol, smoking, and the risk of incident epithelial ovarian cancer. Cancer 112:1169–1177PubMedCrossRefGoogle Scholar
  351. Urban RR, He H, Alfonso R, Hardesty MM, Gray HJ, Goff BA (2016) Ovarian cancer outcomes: predictors of early death. Gynecol Oncol 140:474–480PubMedCrossRefGoogle Scholar
  352. Uzan C, Berretta R, Rolla M et al (2012a) Management and prognosis of endometrioid borderline tumors of the ovary. Surg Oncol 21:178–184PubMedCrossRefGoogle Scholar
  353. Uzan C, Dufeu-Lefebre M, Fauvet R et al (2012b) Management and prognosis of clear cell borderline ovarian tumor. Int J Gynecol Cancer 22:993–999PubMedCrossRefGoogle Scholar
  354. Uzan C, Dufeu-Lefebre M, Fauvet R et al (2012c) Management and prognosis of borderline ovarian Brenner tumors. Int J Gynecol Cancer 22:1332–1336PubMedCrossRefGoogle Scholar
  355. Uzan C, Zanini-Grandon A-S, Bentivegna E et al (2015) Outcome of patients with advanced-stage borderline ovarian tumors after a first peritoneal noninvasive recurrence: impact on further management. Int J Gynecol Cancer 25:830–836PubMedCrossRefGoogle Scholar
  356. van Driel WJ, Koole SN, Sikorska K et al (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 378:230–240CrossRefGoogle Scholar
  357. Vang R, Gown AM, Barry TS et al (2006a) Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases. Am J Surg Pathol 30:1130–1139PubMedCrossRefGoogle Scholar
  358. Vang R, Gown AM, Barry TS et al (2006b) Ovarian atypical proliferative (borderline) mucinous tumors: gastrointestinal and seromucinous (endocervical-like) types are immunophenotypically distinctive. Int J Gynecol Pathol 25:83–89PubMedCrossRefGoogle Scholar
  359. Vang R, Gown AM, Barry TS et al (2006c) Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: an analysis of 124 cases. Mod Pathol 19:97–105PubMedCrossRefGoogle Scholar
  360. Vang R, Gown AM, Wu LS et al (2006d) Immunohistochemical expression of CDX-2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7. Mod Pathol 19:1421–1428PubMedCrossRefGoogle Scholar
  361. Vang R, Gown AM, Farinola M et al (2007a) p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas. Am J Surg Pathol 31:653–663PubMedCrossRefGoogle Scholar
  362. Vang R, Gown AM, Zhao C et al (2007b) Ovarian mucinous tumors associated with mature cystic teratomas: morphologic and immunohistochemical analysis identifies a subset of potential teratomatous origin that shares features of lower gastrointestinal tract mucinous tumors more commonly encountered as secondary tumors in the ovary. Am J Surg Pathol 31:854–869PubMedCrossRefPubMedCentralGoogle Scholar
  363. Vang R, Levine DA, Soslow RA, Zaloudek C, Shih IM, Kurman RJ (2016) Molecular alterations of TP53 are a defining feature of ovarian high-grade serous carcinoma: a rereview of cases lacking TP53 mutations in The Cancer Genome Atlas Ovarian Study. Int J Gynecol Pathol 35:48–55PubMedPubMedCentralCrossRefGoogle Scholar
  364. Vang R, Hannibal CG, Junge J, Frederiksen K, Kjaer SK, Kurman RJ (2017) Long-term behavior of serous borderline tumors subdivided into atypical proliferative tumors and noninvasive low-grade carcinomas a population-based clinicopathologic study of 942 cases. Am J Surg Pathol 41:725–737PubMedPubMedCentralCrossRefGoogle Scholar
  365. Veras E, Mao TL, Ayhan A et al (2009) Cystic and adenofibromatous clear cell carcinoma of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases. Am J Surg Pathol 33:844–853PubMedCrossRefGoogle Scholar
  366. Vercellini P, Crosignani P, Somigliana E et al (2011) The ‘incessant menstruation’ hypothesis: a mechanistic ovarian cancer model with implications for prevention. Hum Reprod 26:2262–2273PubMedCrossRefPubMedCentralGoogle Scholar
  367. Vernooij IJ, Heintz APM, Witteveen PO et al (2008) Specialized care and survival of ovarian cancer patients in the Netherlands: nationwide cohort study. J Natl Cancer Inst 100:399–406PubMedCrossRefPubMedCentralGoogle Scholar
  368. Vierkoetter KR, Ayabe AR, VanDrunen M, Ahn HJ, Shimizu DM, Terada KY (2014) Lynch syndrome in patients with clear cell and endometrioid cancers of the ovary. Gynecol Oncol 135:81–84PubMedPubMedCentralCrossRefGoogle Scholar
  369. Visvanathan K, Shaw P, May BJ et al (Submitted) Fallopian tube lesions in women at high risk for ovarian cancer: a multicenter studyGoogle Scholar
  370. Vitonis AF, Titus-Ernstoff L, Cramer DW (2011) Assessing ovarian cancer risk when considering elective oophorectomy at the time of hysterectomy. Obstet Gynecol 117:1042–1050PubMedPubMedCentralCrossRefGoogle Scholar
  371. Walker JL, Powell CB, Chen LM et al (2015) Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer. Cancer 121:2108–2120PubMedCrossRefGoogle Scholar
  372. Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, Roeb W, Agnew KJ, Stray SM, Wickramanayake A, Norquist B, Pennington KP, Garcia RL, King MC, Swisher EM (2011) Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A 108:18032–18037PubMedPubMedCentralCrossRefGoogle Scholar
  373. Wang Y, Wu R-C, Shwartz LE et al (2015) Clonality analysis of combined Brenner and mucinous tumors of the ovary reveals their monoclonal origin. J Pathol 237:146–151PubMedPubMedCentralCrossRefGoogle Scholar
  374. Webb JR, Milne K, Kroeger DR, Nelson BH (2016) PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. Gynecol Oncol 141:293–302PubMedCrossRefPubMedCentralGoogle Scholar
  375. Wiegand KC, Shah SP, Al-Agha OM et al (2010) ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363:1532–1543PubMedPubMedCentralCrossRefGoogle Scholar
  376. Willis BC, Sloan EA, Atkins KA, Stoler MH, Mills AM (2017) Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium. Mod Pathol 30:1622–1632PubMedCrossRefGoogle Scholar
  377. Wu R, Hendrix-Lucas N, Kuick R et al (2007) Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/β-catenin and PI3K/Pten signaling pathways. Cancer Cell 11:321–323PubMedCrossRefGoogle Scholar
  378. Wu R, Baker SJ, Hu TC, Norman KM, Fearon ER, Cho KR (2013) Type I to type II ovarian carcinoma progression: mutant TRP53 or PIK3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer. Am J Pathol 182:1391–1399PubMedPubMedCentralCrossRefGoogle Scholar
  379. Wu RC, Wang TL, Shih IM (2014) The emerging roles of ARID1A in tumor suppression. Cancer Biol Ther 15:655–664PubMedPubMedCentralCrossRefGoogle Scholar
  380. Wu R, Zhai Y, Kuick R, Karnezis AN, Garcia P, Naseem A, Hu TC, Fearon ER, Cho KR (2016) Impact of oviductal versus ovarian epithelial cell of origin on ovarian endometrioid carcinoma phenotype in the mouse. J Pathol 240:341–351PubMedPubMedCentralCrossRefGoogle Scholar
  381. Wu X, Wu L, Kong B et al (2017) The first nationwide multicenter prevalence study of germline BRCA1 and BRCA2 mutations in Chinese ovarian cancer patients. Int J Gynecol Cancer 27:1650–1657PubMedCrossRefPubMedCentralGoogle Scholar
  382. Xing D, Rahmanto S, Zeppernick F et al (2017) Mutation of NRAS is a rare genetic event in ovarian low grade serous carcinoma. Hum Pathol 68:87–91PubMedCrossRefPubMedCentralGoogle Scholar
  383. Yamamoto S, Tsuda H, Takano M et al (2008) Clear cell adenofibroma can be a clonal precursor for clear cell adenocarcinoma of the ovary: a possible alternative clear cell carcinogenic pathway. J Pathol 216:103–110PubMedPubMedCentralGoogle Scholar
  384. Yamamoto S, Kasajima A, Takano M et al (2011) Validation of the histologic grading for ovarian clear cell adenocarcinoma: a retrospective multi-institutional study by the Japan Clear Cell Carcinoma Study Group. Int J Gynecol Pathol 30:129–138PubMedCrossRefGoogle Scholar
  385. Yang HP, Anderson WF, Rosenberg PS et al (2013) Ovarian cancer incidence trends in relation to changing patterns of menopausal hormone therapy use in the United States. J Clin Oncol 31:2146–2151PubMedPubMedCentralCrossRefGoogle Scholar
  386. Yang HP, Murphy KR, Pfeiffer RM et al (2016) Lifetime number of ovulatory cycles and risks of ovarian and endometrial cancer among postmenopausal women. Am J Epidemiol 183:800–814PubMedPubMedCentralCrossRefGoogle Scholar
  387. Yemelyanova AV, Cosin JA, Bidus MA, Boice CR, Seidman JD (2008a) Pathology of stage I versus stage III ovarian carcinoma with implications for pathogenesis and screening. Int J Gynecol Cancer 18:465–469PubMedCrossRefGoogle Scholar
  388. Yemelyanova A, Mao TL, Nakayama N (2008b) Low grade serous carcinoma of the ovary displaying a macropapillary pattern. Am J Surg Pathol 32:1800–1806PubMedPubMedCentralCrossRefGoogle Scholar
  389. Yemelyanova A, Vang R, Judson K et al (2008c) Distinction of primary and metastatic mucinous tumors involving the ovary: analysis of size and laterality data by primary site with reevaluation of an algorithm for tumor classification. Am J Surg Pathol 32:128–138PubMedCrossRefGoogle Scholar
  390. Yemelyanova A, Vang R, Kshirsagar M et al (2011) Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol 24:1248–1253PubMedCrossRefGoogle Scholar
  391. Zaino RJ, Brady MF, Lele SM, Michael H, Greer B, Bookman MA (2011) Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group study. Cancer 117:554–562PubMedCrossRefGoogle Scholar
  392. Zeppernick F, Ardighieri L, Hannibal CG et al (2014) BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors. Am J Surg Pathol 38:1603–1611PubMedPubMedCentralCrossRefGoogle Scholar
  393. Zhai Y, Wu R, Kuick R, Sessine MS, Schulman S, Green M, Fearon ER, Cho KR (2017) High-grade serous carcinomas arise in the mouse oviduct via defects linked to the human disease. J Pathol 243:16–25PubMedPubMedCentralCrossRefGoogle Scholar
  394. Zhao C, Wu LS-F, Barner R (2011) Pathogenesis of ovarian clear cell adenofibroma, atypical proliferative (borderline) tumor, and carcinoma: clinicopathologic features of tumors with endometriosis or adenofibromatous components support two related pathways of tumor development. J Cancer 2:94–106PubMedPubMedCentralCrossRefGoogle Scholar
  395. Zhou AG, Levinson KL, Rosenthal DL, VandenBussche CJ (2018) Performance of ovarian cyst fluid fine-needle aspiration cytology. Cancer Cytopathol 126:112–121PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Jeffrey D. Seidman
    • 1
    Email author
  • Brigitte M. Ronnett
    • 2
  • Ie-Ming Shih
    • 3
  • Kathleen R. Cho
    • 4
  • Robert J. Kurman
    • 5
  1. 1.Center for Devices and Radiological Health, Office of In Vitro Diagnostics and Radiological HealthFood and Drug AdministrationSilver SpringUSA
  2. 2.Department of Pathology, Division of Gynecologic PathologyJohns Hopkins University School of MedicineBaltimoreUSA
  3. 3.Gynecologic Pathology Laboratory in the Department of Gynecology and ObstetricsJohns Hopkins University School of MedicineBaltimoreUSA
  4. 4.Department of PathologyUniversity of Michigan Medical SchoolAnn ArborUSA
  5. 5.Departments of Gynecology, Obstetrics, Pathology and Oncology, Division of Gynecologic PathologyJohns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations